Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.